ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 07:14:38 pm | |||
| 733.5 USD | +1.19% |
|
734 | +0.07% |
| Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.79% | - | |
| 3.30% | 92 M€ | +0.06% | - | |
| 3.20% | 2 M€ | -.--% | - | |
| 3.19% | 9 M€ | -.--% | - | |
| 2.82% | 1 M€ | +11.94% | - | |
| 2.82% | 3 M€ | +7.32% | - | |
| 2.82% | 13 M€ | -.--% | - | |
| 2.71% | 5 M€ | -72.95% | - | |
| 2.58% | 786 M€ | -.--% | ||
| 2.58% | 23 M€ | -.--% | - | |
| 2.56% | 284 M€ | -.--% | ||
| 2.18% | 2 M€ | +14.69% | - | |
| 1.98% | 1,448 M€ | -.--% | - | |
| 1.98% | 219 M€ | +17.17% | - | |
| 1.96% | 36 M€ | -.--% | ||
| 1.95% | 2 M€ | +6.77% | ||
| 1.86% | 9 M€ | -4.31% | - | |
| 1.78% | 8 M€ | +2.44% | ||
| 1.70% | 1 M€ | +0.04% | ||
| 1.57% | 559 M€ | +14.30% | - | |
| 1.57% | 1,848 M€ | +18.39% | - | |
| 1.49% | 273 M€ | -.--% | ||
| 1.49% | 655 M€ | -.--% | - | |
| 1.49% | 1,174 M€ | +23.54% | ||
| 1.46% | 414 M€ | +10.21% | - | |
| 1.46% | 1,006 M€ | -.--% | - | |
| 1.41% | 29 M€ | -.--% | - | |
| 1.41% | 322 M€ | +13.88% | - | |
| 1.21% | 276 M€ | +11.40% | - |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
733.5
USD
Average target price
813.3
USD
Spread / Average Target
+10.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
